HYPR
Hyperfine, Inc.
There isn't enough reported data to score HYPR yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
HYPR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
HYPR's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HYPR PE Valuation
HYPR has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HYPR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect HYPR's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
HYPR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.29 | +$0.23 |
| Q2 2026 | -$0.37 | +$0.15 |
| Q1 2026 | -$0.40 | +$0.14 |
| Q4 2025 | -$0.43 | +$0.13 |
| Q3 2025 | -$0.52 | +$0.05 |
| Q2 2025 | -$0.52 | +$0.06 |
| Q1 2025 | -$0.54 | +$0.05 |
| Q4 2024 | -$0.56 | +$0.06 |
HYPR is still losing money, but far less than before: $0.29 per share over the past year, against $1.04 at its worst in late 2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over HYPR on earnings quality, reporting a profit while its opponent remains loss making.
HYPR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6M | +73% |
| Q2 2026 | $3.9M | +45% |
| Q1 2026 | $3.9M | +83% |
| Q4 2025 | $5.3M | +128% |
| Q3 2025 | $3.4M | -5.7% |
| Q2 2025 | $2.7M | -26% |
| Q1 2025 | $2.1M | -35% |
| Q4 2024 | $2.3M | -14% |
HYPR's revenue has grown year over year for four quarters in a row: $6M last quarter, up 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -122% | +138 points |
| Q2 2026 | -217% | +139 points |
| Q1 2026 | -219% | +291 points |
| Q4 2025 | -145% | +319 points |
| Q3 2025 | -260% | +41 points |
| Q2 2025 | -356% | -57 points |
| Q1 2025 | -510% | -187 points |
| Q4 2024 | -464% | -31 points |
HYPR's operating margin was −122% last quarter, up 138 points from the same quarter a year ago, near the top of its range since 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HYPR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HYPR on profitability, with a higher operating margin.
HYPR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.1M | -$392K |
| Q2 2026 | -$7.3M | +$1.1M |
| Q1 2026 | -$9.3M | +$471K |
| Q4 2025 | -$5.3M | +$3.1M |
| Q3 2025 | -$5.7M | +$3M |
| Q2 2025 | -$8.4M | +$1M |
| Q1 2025 | -$9.7M | +$2.9M |
| Q4 2024 | -$8.4M | +$1.8M |
HYPR has burned cash in almost every quarter: −$28M over the past year, against −$32M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over HYPR on cash generation, producing positive trailing cash flow while its opponent burns cash.
HYPR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.3% | +6.3M shares |
| 1 year | +34% | +27.1M shares |
| 3 years | +48% | +34.6M shares |
HYPR has 106M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over HYPR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HYPR Net Leverage
HYPR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
HYPR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.6 | Neutral |
| Stochastic | 7.7 | Oversold |
HYPR's weekly RSI is 35 (neutral) and its Stochastic is 8 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HYPR PE vs Healthcare Sector
HYPR has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HYPR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.78 | 13% below |
| 20 week MA | $0.87 | 22% below |
| 50 week MA | $1.10 | 38% below |
| 100 week MA | $1.06 | 36% below |
| 200 week MA | $1.19 | 43% below |
HYPR is in a downtrend: it's below all five of its weekly moving averages, and 43% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over HYPR on trend strength, trading above more of its moving averages.
HYPR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.1 | $9.19 | -9% |
| 2022 | $9.19 | $0.89 | -90% |
| 2023 | $0.89 | $1.12 | +26% |
| 2024 | $1.12 | $0.89 | -21% |
| 2025 | $0.89 | $1.06 | +19% |
| 2026 YTD | $1.06 | $0.68 | -36% |
HYPR has finished lower in three of the last five years. It's down 36% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HYPR on returns for 2026, with the stronger performance.